Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost “Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost” has been added to your cart. View cart €15.00 Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost quantity Add to cart Category: Articles Tag: Volume 3 Description Description Authors: Janet B. Serle, Jake Radell Related products The interleukin-20 (IL-20) story €15.00 Add to cart Medical device basics €15.00 Add to cart The 810 Nm I.R. Diode Laser in the pivotal paradigm shift from laser photocoagulation to laser photostimulation €15.00 Add to cart Cerebrospinal fluid dynamics and primary open-angle glaucoma €15.00 Add to cart